There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Data availability:

Comments

Comment on this article

Cited by 1

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer
Authors: M S Michael, George N Pavlakis, P. CLINGAN …

See all cited by

Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC)

Read this article at

Related collections

Scientific Ocean Drilling Expedition Research Results

Comments

Comment on this article

Similar content 718

Cited by 1